Agendia will use Rubicon Genomics' whole-genome RNA amplification technology in its breast cancer diagnostic tests, Rubicon said today.
Under a clinical supply agreement, Agendia will apply Rubicon's TransPlex technology to analyze formalin-fixed, paraffin-embedded patient samples on Agendia's Symphony suite of breast cancer diagnostics.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
